Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Cyy-272
Cat. No.:
OB0425LY-245
Appearance:
Solid
Purity:
≥95%
Identity:
Confirmed by NMR.
Size:
Add to basket
Product Overview
Description:
Cyy-272 is a special active JNK inhibitor that inhibits JNK1, JNK3, and JNK3.
Synonyms:
Cyy 272; 2644673-01-6; Cyy272
CAS No.:
2644673-01-6
Compound CID:
156704689
Formula:
C23H23F2N7
Formula Weight:
435.47
Specification
Target:
JNK; Apoptosis
Pathway:
MAPK/ERK pathway; Apoptosis
Storage:
Storage at -20°C.
Applications:
Cyy-272 can be used in studies of obesity cardiomyopathy.
